A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, double-blind, placebo-controlled, randomized study to assess
the safety and efficacy of elagolix versus placebo in premenopausal 18 to 49 year old women
with moderate to severe endometriosis-associated pain.